Personas / Equipo Humano

Guillem Pascual Pastó

Buscador de publicaciones

Publicaciones

  • Pascual-Pastó G, Bazan-Peregrino M, Gene-Olaciregui N, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa MG, Paco-Mercader S, Vilà-Ubach M, Cuadrado-Vilanova M, Castillo H, Botteri G, García-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell-Burriel M, Roldan-Molina M, König A, Suñol M, Claverol J, Lavarino C, de Torres C, Fu L, Radvanyi F, Munier FL, Català-Mora J, Mora J, Alemany R, Cascallo M, Chantada G and Carcaboso AM.

    Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01

    Science Translational Medicine . 11(476): 9321. Nº de citas: 103

    [doi:10.1126/scitranslmed.aat9321]

  • Manzanares-Quintela A, Restrepo-Perdomo CA, Botteri G, Castillo H, Pascual-Pastó G, Cano F, Garcia-Alvarez L, Monterrubio C, Ruiz B, Vazquez M, Suñol M, Mora J, Tornero JA, Sosnik A and Carcaboso AM.

    Tissue Compatibility of SN-38-Loaded Anticancer Nanofiber Matrices

    Advanced Healthcare Materials . 7(15): . Nº de citas: 5

    [doi:10.1002/adhm.201800255]

  • García-Domínguez DJ, Hontecillas-Prieto L, Rodríguez-Núñez P, Pascual-Pastó G, Vilà-Ubach M, García-Mejías R, Robles MJ, Tirado OM, Mora J, Carcaboso AM and de Álava E.

    The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma.

    Oncotarget . 9(59): 31397-31410. Nº de citas: 25

    [doi:10.18632/oncotarget.25829]

  • Bukchin A, Pascual-Pastó G, Cuadrado-Vilanova M, Castillo-Ecija H, Monterrubio C, Gene-Olaciregui N, Vilà-Ubach M, Ordeix L, Mora J, Carcaboso AM and Sosnik A.

    Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas

    JOURNAL OF CONTROLLED RELEASE . 276: 59-71. Nº de citas: 28

    [doi:10.1016/j.jconrel.2018.02.034]

  • Pascual-Pastó G, Gene-Olaciregui N, Opezzo JAW, Castillo-Ecija H, Cuadrado-Vilanova M, Paco-Mercader S, Rivero EM, Vilà-Ubach M, Restrepo-Perdomo CA, Torrebadell-Burriel M, Suñol M, Schaquevich P, Mora J, Bramuglia GF, Chantada G and Carcaboso AM.

    Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier

    JOURNAL OF CONTROLLED RELEASE . 264: 34-44. Nº de citas: 17

    [doi:10.1016/j.jconrel.2017.08.018]

  • Monterrubio C, Paco-Mercader S, Gene-Olaciregui N, Pascual-Pastó G, Vilà-Ubach M, Cuadrado-Vilanova M, Ferrandiz MM, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NV, Mora J, Sosnik A and Carcaboso AM.

    Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8

    JOURNAL OF CONTROLLED RELEASE . 255: 108-119. Nº de citas: 44

    [doi:10.1016/j.jconrel.2017.04.016]

  • Pascual-Pastó G, Gene-Olaciregui N, Vilà-Ubach M, Paco-Mercader S, Monterrubio C, Rodriguez E, Winter U, Batalla-Vilacís M, Català-Mora J, Salvador-Hernandez H, Parareda A, Schaiquevich P, Suñol M, Mora J, Lavarino C, de Torres C, Chantada G and Carcaboso AM.

    Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination

    CANCER LETTERS . 380(1): 10-19. Nº de citas: 30

    [doi:10.1016/j.canlet.2016.06.012]

  • Winter U, Mena HA, Negrotto S, Arana E, Pascual-Pastó G, Laurent V, Suñol M, Chantada G, Carcaboso AM and Schaiquevich P.

    Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells

    PLoS One . 11(7): . Nº de citas: 21

    [doi:10.1371/journal.pone.0160094]

  • Monterrubio C, Pascual-Pastó G, Cano F, Vilà-Ubach M, Manzanares-Quintela A, Schaiquevich P, Tornero JA, Sosnik A, Mora J and Carcaboso AM.

    SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery

    BIOMATERIALS . 79: 69-78. Nº de citas: 46

    [doi:10.1016/j.biomaterials.2015.11.055]

  • Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, Del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pastó G, San-Segundo L, Vilà-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J and de Álava E.

    The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

    Oncotarget . 6(22): 18875-18890. Nº de citas: 72

    [doi:10.18632/oncotarget.4303]